Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CTSA | P10619 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198917 | 0.88 | KDM4E (0.59) | KDM4EERN1KMT2ASLC13A5CYP1A2 | |
| SCHEMBL9140016 | 0.87 | KDM4E (0.46) | KDM4EERN1KMT2ASLC13A5CYP1A2 | |
| SCHEMBL534325 | 0.86 | RXRA (0.58) | KDM4ESLC13A5CYP19A1RXRARXRB | |
| SCHEMBL15473215 | 0.86 | KMT2A (0.57) | KDM4EERN1KMT2ASLC13A5CYP1A2 | |
| SCHEMBL533061 | 0.80 | CYP3A4 (0.52) | KDM4EERN1KMT2ACYP1A2CYP19A1 | |
| SCHEMBL1337028 | 0.80 | KDM4E (0.57) | KDM4EERN1KMT2ASLC13A5RXRA | |
| SCHEMBL6200091 | 0.80 | KDM4E (0.51) | KDM4EERN1KMT2ASLC13A5CYP1A2 | |
| SCHEMBL2574296 | 0.79 | SLC13A5 (0.54) | KDM4EERN1KMT2ASLC13A5RXRA | |
| SCHEMBL693938 | 0.79 | HSD17B1 (0.43) | LTA4HRXRARXRBCTSA | |
| SCHEMBL197506 | 0.78 | CYP19A1 (0.64) | KDM4EKMT2ACYP1A2CYP19A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | KDM4E 2779/4885ERN1 3359/4885KMT2A 723/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | KDM4E 2804/4885ERN1 3533/4885KMT2A 820/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | KDM4E 3706/4885ERN1 4741/4885KMT2A 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.